Proteomic Contributions to Personalized Cancer Care

被引：73

作者：

Koomen, John M. ^{[1
]}

Haura, Eric B. ^{[1
]}

Bepler, Gerold ^{[1
]}

Sutphen, Rebecca ^{[1
]}

Remily-Wood, Elizabeth R. ^{[1
]}

Benson, Kaaron ^{[1
]}

Hussein, Mohamad ^{[1
]}

Hazlehurst, Lori A. ^{[1
]}

Yeatman, Timothy J. ^{[1
]}

Hildreth, Lynne T. ^{[1
]}

Sellers, Thomas A. ^{[1
]}

Jacobsen, Paul B. ^{[1
]}

Fenstermacher, David A. ^{[1
]}

Dalton, William S. ^{[1
]}

机构：

[1] Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA

来源：

MOLECULAR & CELLULAR PROTEOMICS | 2008年 / 7卷 / 10期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1074/mcp.R800002-MCP200

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Cancer impacts each patient and family differently. Our current understanding of the disease is primarily limited to clinical hallmarks of cancer, but many specific molecular mechanisms remain elusive. Genetic markers can be used to determine predisposition to tumor development, but molecularly targeted treatment strategies that improve patient prognosis are not widely available for most cancers. Individualized care plans, also described as personalized medicine, still must be developed by understanding and implementing basic science research into clinical treatment. Proteomics holds great promise in contributing to the prevention and cure of cancer because it provides unique tools for discovery of biomarkers and therapeutic targets. As such, proteomics can help translate basic science discoveries into the clinical practice of personalized medicine. Here we describe how biological mass spectrometry and proteome analysis interact with other major patient care and research initiatives and present vignettes illustrating efforts in discovery of diagnostic biomarkers for ovarian cancer, development of treatment strategies in lung cancer, and monitoring prognosis and relapse in multiple myeloma patients. Molecular & Cellular Proteomics 7: 1780-1794, 2008.

引用

页码：1780 / 1794

页数：15

共 92 条

[1] The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins [J].

Adachi, Jun ;

Kumar, Chanchal ;

Zhang, Yanling ;

Olsen, Jesper V. ;

Mann, Matthias .

GENOME BIOLOGY, 2006, 7 (09)

[2] Toward a human blood serum proteome - Analysis by multidimensional separation coupled with mass spectrometry [J].

Adkins, JN ;

Varnum, SM ;

Auberry, KJ ;

Moore, RJ ;

Angell, NH ;

Smith, RD ;

Springer, DL ;

Pounds, JG .

MOLECULAR & CELLULAR PROTEOMICS, 2002, 1 (12) :947-955

[3] A proteomic study of the HUPO Plasma Proteome Project's pilot samples using an accurate mass and time tag strategy [J].

Adkins, JN ;

Monroe, ME ;

Auberry, KJ ;

Shen, YF ;

Jacobs, JM ;

Camp, DG ;

Vitzthum, F ;

Rodland, KD ;

Zangar, RC ;

Smith, RD ;

Pounds, JG .

PROTEOMICS, 2005, 5 (13) :3454-3466

[4] Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer [J].

Ahmed, N ;

Oliva, KT ;

Barker, G ;

Hoffmann, P ;

Reeve, S ;

Smith, IA ;

Quinn, MA ;

Rice, GE .

PROTEOMICS, 2005, 5 (17) :4625-4636

[5]

Alaiya AA, 1997, INT J CANCER, V73, P678, DOI 10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO

[6]

2-2

[7]

Alaiya AA, 1999, ELECTROPHORESIS, V20, P1039, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<1039::AID-ELPS1039>3.3.CO

[8]

2-W

[9]

*AM CANC SOC INC, 2008, CANC STAT 2008

[10] Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins [J].

Anderson, L ;

Hunter, CL .

MOLECULAR & CELLULAR PROTEOMICS, 2006, 5 (04) :573-588

← 1 2 3 4 5 6 7 8 9 10 →